HRT Treatment Selector

Charts revised November 2017. Full information available at www.hiv-druginteractions.org

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF
	Estradiol	↓[a]	↓[a]	↓[a]	↓[a]	↓[a]	↓[a]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
Progestins (HRT)	**Drospirenone**	↑[b]	↑[b]	↑[b]	↓[a]	↓[a]	↓[a]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑[b]	↑[b]
	Dydrogesterone	↑[b]	↑[b]	↑[b]	↓[a]	↓[a]	↓[a]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑[b]	↑[b]
	Levonorgestrel	↑[b]	↑[b]	↑[b]	↓[a]	↓[a]	↓[a]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑[b]	↑[b]
	Medroxy-progesterone (oral)	↑[b]	↑[b]	↑[b]	↓[a]	↓[a]	↓[a]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑[b]	↑[b]
	Norethisterone (Norethindrone)	↑[b]	↑[b]	↑[b]	↓[a]	↓[a]	↓[a]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑[b]	↑[b]
	Norgestrel	↑[b]	↑[b]	↑[b]	↓[a]	↓[a]	↓[a]	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑[b]	↑[b]

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

↑ Potential increased exposure of the hormone

↓ Potential decreased exposure of the hormone

↔ No significant effect

a Monitor for signs of estrogen deficiency.

b The clinical significance of increased progestin exposure in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown.

Abbreviations ATV atazanavir DRV darunavir LPV lopinavir /r ritonavir EFV efavirenz ETV etravirine NVP nevirapine RPV rilpivirine MVC maraviroc DTG dolutegravir RAL raltegravir
ABC abacavir FTC emtricitabine 3TC lamivudine TDF tenofovir disoproxil fumarate ZDV zidovudine E/C/F/ Elvitegravir/Cobicistat/FTC TAF tenofovir alafenamide